331
Participants
Start Date
March 31, 2000
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
Bleomycin
10 mg/m2 IV day 8 during cycles 1 to 8
Etoposide
200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
Doxorubicin
35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
Cyclophosphamide
1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
Vincristine
1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
Procarbazine
100 mg/m2 po from day 1 to 7 during cycles 1 to 8
Prednisone
40 mg/m2 po from day 1 to 14 during cycles 1 to 8
Doxorubicin
25 mg/m2 iv on days 1 and 15 in each cycle
Bleomycin
10 mg/m2 iv on days 1 and 15 in each cycle
Vinblastine
6 mg/m2 iv on days 1 and 15 in each cycle
Dacarbazine
375 mg/m2 iv on days 1 and 15 in each cycle
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milan
Fondazione Michelangelo
OTHER